Gene therapy for lipoprotein disorders

Area of Science:

• Lipid Metabolism and Genetics
• Molecular Medicine
• Translational Therapeutics

Background:

• Current treatments for dyslipidaemia, including hypercholesterolaemia and hypertriglyceridaemia, are insufficient for many patients.
• Inherited disorders of intracellular lipid metabolism also present significant therapeutic challenges.
• Refractory lipid disorders necessitate novel treatment strategies beyond conventional approaches.

Purpose of the Study:

• To explore somatic gene therapy as a potential treatment for various lipid disorders.
• To review the current status of preclinical and clinical research in gene therapy for dyslipidaemia.
• To assess the future prospects of gene therapy in managing complex lipid metabolism disorders.

Main Methods:

• Review of existing preclinical proof-of-principle studies for somatic gene therapy in lipid disorders.
• Analysis of the conducted clinical trial for homozygous familial hypercholesterolaemia.
• Assessment of the pipeline for future gene therapy clinical trials in dyslipidaemia.

Main Results:

• Preclinical evidence supports the potential of somatic gene therapy for several lipid disorders.
• A clinical trial has been successfully conducted for homozygous familial hypercholesterolaemia.
• Gene therapy approaches are advancing towards clinical application for dyslipidaemia.

Conclusions:

• Somatic gene therapy represents a promising therapeutic frontier for refractory lipid disorders.
• The progression from preclinical studies to clinical trials indicates the feasibility of gene therapy for dyslipidaemia.
• Further clinical trials are anticipated, highlighting the growing role of gene therapy in managing lipid metabolism diseases.